We have a team of editors dedicted to bringing you breaking news from within the medical sector. All our articles are completely unbiased and based on the industry as a whole. Please filter the news by your preferred profession below.
Apply to us in seconds, let us find you the perfect job.
Register as an Biomedical ScientistRefer a friend and earn £200 after they finish 4 weeks work!
Refer an Biomedical Scientist
Friday 7th October 2011
Doctors may be able to use bone marrow cells to slow the growth of tumours, following the results of a research programme that will be published in the November issue of the American Journal of Pathology.
Bone marrow-derived cells (BMDCs) were investigated in a mouse model that was used to track the migration of cells while tumours grew.
Monitoring tumour growth via optical imaging, researchers at the Penn State Hershey Cancer Institute found that the tumours contained many types of BMDCs, and that their growth was reduced in mice that received bone marrow transplants.
"Our results provide an excellent in vivo experimental model where the temporal dynamics of tumour-infiltrating BMDCs may be monitored in an immunocompetent host and novel therapies targeting BMDCs for the inhibition of tumour progression may be investigated," said Wafik S El-Deiry of the Penn State Hershey Cancer Institute.
"In the future, it may be possible to use specific identified tumour-infiltrating BMDCs to deliver therapeutic cargo."
While cancer has been traditionally viewed by doctors as a disease in which transformed cells grow and invade living tissues, the researchers believe their findings suggest the disease is in fact more complex than this.
They believe cancer is a disease that takes place in a heterogeneous microenvironment where multiple cellular interactions are occurring within the affected tissue.
"This ongoing war on cancer within this tumor microenvironment has surprising twists and turns," added Professor El-Deiry.
The research comes soon after a new study, due to be published in an upcoming issue of Cancer Epidemiology Biomarkers and Prevention, which suggested that liver cancer incidence rates are continuing to increase in low-risk parts of the world, such as North America, while decreasing in higher-risk countries in Asia.
It is believed the trend could be partly down to increased chronic HCV infection as a result of unscreened blood transfusions and intravenous drug use.
Written by Angela Newbury
Experienced BMS in Cytology required for a locum job opportunity to work in the North West of England. Based within an NHS setting...
Full infoLocum BMS Immunochemistry HPC registered Job Title: Locum BMS Immunochemistry Brief Details Experienced BMS in Biochemistry...
Full infoHPC registered BMS BT/Haematology needed for a Locum Job in London.We are recruiting for a team of highly motivated and experienced...
Full infoCall 0845 230 6666
Fax 0845 230 6677
The Placement Group JustPhysio JustOT
Mediplacements is a member of The Placement Group.
Mediplacements partners with JustPhysio and JustOT